Inhibition of integrin αvβ3 reduces blood-brain barrier breakdown in focal ischemia in rats

Norihito Shimamura, Gerald Matchett, Ihsan Solaroglu, Tamiji Tsubokawa, Hiroki Ohkuma, John Zhang

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Ischemic stroke is a major cause of morbidity and mortality in industrialized nations. We tested the effect of postischemic treatment of cyclo-RGDfV (cRGDfV), a selective inhibitor of integrin αvβ3, in the middle cerebral artery occlusion (MCAO) model of ischemic stroke in rats. Rats were randomly divided into three groups: sham operation (n = 13), MCAO with no treatment (n = 18), and MCAO with cRGDfV treatment (n = 28). Focal ischemia was induced with the suture occlusion method for 2 hr, and treatment was given 1 hr after reperfusion (3 hr after ischemia). All animals were sacrificed 24 hr after reperfusion. Assessment included neurological scores, infarction volumes, brain water content, Evans blue exudation, IgG exudation, histology, immunohistochemistry, and Western blotting. Treatment with cRGDfV ameliorated neurological deficits, reduced brain edema, and reduced exudation of Evans blue dye and IgG, but failed to reduce infarction volumes. Western blotting showed a reduction in phosphorylation of one subset of vascular endothelial growth factor (VEGF) receptors in the cRGDfV treatment group. Western blotting also demonstrated a significant reduction of fibrinogen in the cRGDfV treatment group. We conclude that poststroke treatment with cRGDfV reduces blood-brain barrier breakdown in focal ischemia, possibly through inhibition of VEGF-mediated vascular breakdown.

Original languageEnglish (US)
Pages (from-to)1837-1847
Number of pages11
JournalJournal of Neuroscience Research
Volume84
Issue number8
DOIs
StatePublished - Dec 2006

Fingerprint

Blood-Brain Barrier
Integrins
Ischemia
Middle Cerebral Artery Infarction
Evans Blue
Western Blotting
Therapeutics
Reperfusion
Immunoglobulin G
Stroke
Brain Infarction
Vascular Endothelial Growth Factor Receptor
Brain Edema
Developed Countries
Fibrinogen
Infarction
Sutures
Vascular Endothelial Growth Factor A
Blood Vessels
cyclo(arginyl-glycyl-aspartyl-phenylalanyl-valyl)

Keywords

  • cRGDfV
  • Flk-1
  • Integrin αvβ3
  • MCAO
  • VEGF

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Inhibition of integrin αvβ3 reduces blood-brain barrier breakdown in focal ischemia in rats. / Shimamura, Norihito; Matchett, Gerald; Solaroglu, Ihsan; Tsubokawa, Tamiji; Ohkuma, Hiroki; Zhang, John.

In: Journal of Neuroscience Research, Vol. 84, No. 8, 12.2006, p. 1837-1847.

Research output: Contribution to journalArticle

Shimamura, Norihito ; Matchett, Gerald ; Solaroglu, Ihsan ; Tsubokawa, Tamiji ; Ohkuma, Hiroki ; Zhang, John. / Inhibition of integrin αvβ3 reduces blood-brain barrier breakdown in focal ischemia in rats. In: Journal of Neuroscience Research. 2006 ; Vol. 84, No. 8. pp. 1837-1847.
@article{9e57a7e2f27040228e2670fa0d719b7e,
title = "Inhibition of integrin αvβ3 reduces blood-brain barrier breakdown in focal ischemia in rats",
abstract = "Ischemic stroke is a major cause of morbidity and mortality in industrialized nations. We tested the effect of postischemic treatment of cyclo-RGDfV (cRGDfV), a selective inhibitor of integrin αvβ3, in the middle cerebral artery occlusion (MCAO) model of ischemic stroke in rats. Rats were randomly divided into three groups: sham operation (n = 13), MCAO with no treatment (n = 18), and MCAO with cRGDfV treatment (n = 28). Focal ischemia was induced with the suture occlusion method for 2 hr, and treatment was given 1 hr after reperfusion (3 hr after ischemia). All animals were sacrificed 24 hr after reperfusion. Assessment included neurological scores, infarction volumes, brain water content, Evans blue exudation, IgG exudation, histology, immunohistochemistry, and Western blotting. Treatment with cRGDfV ameliorated neurological deficits, reduced brain edema, and reduced exudation of Evans blue dye and IgG, but failed to reduce infarction volumes. Western blotting showed a reduction in phosphorylation of one subset of vascular endothelial growth factor (VEGF) receptors in the cRGDfV treatment group. Western blotting also demonstrated a significant reduction of fibrinogen in the cRGDfV treatment group. We conclude that poststroke treatment with cRGDfV reduces blood-brain barrier breakdown in focal ischemia, possibly through inhibition of VEGF-mediated vascular breakdown.",
keywords = "cRGDfV, Flk-1, Integrin αvβ3, MCAO, VEGF",
author = "Norihito Shimamura and Gerald Matchett and Ihsan Solaroglu and Tamiji Tsubokawa and Hiroki Ohkuma and John Zhang",
year = "2006",
month = "12",
doi = "10.1002/jnr.21073",
language = "English (US)",
volume = "84",
pages = "1837--1847",
journal = "Journal of Neuroscience Research",
issn = "0360-4012",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - Inhibition of integrin αvβ3 reduces blood-brain barrier breakdown in focal ischemia in rats

AU - Shimamura, Norihito

AU - Matchett, Gerald

AU - Solaroglu, Ihsan

AU - Tsubokawa, Tamiji

AU - Ohkuma, Hiroki

AU - Zhang, John

PY - 2006/12

Y1 - 2006/12

N2 - Ischemic stroke is a major cause of morbidity and mortality in industrialized nations. We tested the effect of postischemic treatment of cyclo-RGDfV (cRGDfV), a selective inhibitor of integrin αvβ3, in the middle cerebral artery occlusion (MCAO) model of ischemic stroke in rats. Rats were randomly divided into three groups: sham operation (n = 13), MCAO with no treatment (n = 18), and MCAO with cRGDfV treatment (n = 28). Focal ischemia was induced with the suture occlusion method for 2 hr, and treatment was given 1 hr after reperfusion (3 hr after ischemia). All animals were sacrificed 24 hr after reperfusion. Assessment included neurological scores, infarction volumes, brain water content, Evans blue exudation, IgG exudation, histology, immunohistochemistry, and Western blotting. Treatment with cRGDfV ameliorated neurological deficits, reduced brain edema, and reduced exudation of Evans blue dye and IgG, but failed to reduce infarction volumes. Western blotting showed a reduction in phosphorylation of one subset of vascular endothelial growth factor (VEGF) receptors in the cRGDfV treatment group. Western blotting also demonstrated a significant reduction of fibrinogen in the cRGDfV treatment group. We conclude that poststroke treatment with cRGDfV reduces blood-brain barrier breakdown in focal ischemia, possibly through inhibition of VEGF-mediated vascular breakdown.

AB - Ischemic stroke is a major cause of morbidity and mortality in industrialized nations. We tested the effect of postischemic treatment of cyclo-RGDfV (cRGDfV), a selective inhibitor of integrin αvβ3, in the middle cerebral artery occlusion (MCAO) model of ischemic stroke in rats. Rats were randomly divided into three groups: sham operation (n = 13), MCAO with no treatment (n = 18), and MCAO with cRGDfV treatment (n = 28). Focal ischemia was induced with the suture occlusion method for 2 hr, and treatment was given 1 hr after reperfusion (3 hr after ischemia). All animals were sacrificed 24 hr after reperfusion. Assessment included neurological scores, infarction volumes, brain water content, Evans blue exudation, IgG exudation, histology, immunohistochemistry, and Western blotting. Treatment with cRGDfV ameliorated neurological deficits, reduced brain edema, and reduced exudation of Evans blue dye and IgG, but failed to reduce infarction volumes. Western blotting showed a reduction in phosphorylation of one subset of vascular endothelial growth factor (VEGF) receptors in the cRGDfV treatment group. Western blotting also demonstrated a significant reduction of fibrinogen in the cRGDfV treatment group. We conclude that poststroke treatment with cRGDfV reduces blood-brain barrier breakdown in focal ischemia, possibly through inhibition of VEGF-mediated vascular breakdown.

KW - cRGDfV

KW - Flk-1

KW - Integrin αvβ3

KW - MCAO

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=33845409421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845409421&partnerID=8YFLogxK

U2 - 10.1002/jnr.21073

DO - 10.1002/jnr.21073

M3 - Article

C2 - 17016855

AN - SCOPUS:33845409421

VL - 84

SP - 1837

EP - 1847

JO - Journal of Neuroscience Research

JF - Journal of Neuroscience Research

SN - 0360-4012

IS - 8

ER -